Dasatinib

製品コードS1021 別名:BMS-354825

Dasatinib化学構造

分子量(MW):488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 23240.00
JPY 24402.00
JPY 61420.00

文献中Selleckの製品使用例(73)

カスタマーフィードバック(13)

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

製品安全説明書

Src阻害剤の選択性比較

生物活性

製品説明 Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
ターゲット
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外試験

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DKd|czKGh? M37Oe2ROW09? Moe2TWM2OD1yLkCwNFA4KM7:TR?= Mm[5NVc6PTZyOEC=
K562 NE\6ZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPPO|IhcA>? NVu2TmZCTE2VTx?= M33QVGlEPTB;MD6wNFEh|ryP NVjqWoh3OTd7NU[wPFA>
M07e MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M32xRlczKGh? NWXkR4Q3TE2VTx?= MoP2TWM2OD1yLkCwNVIh|ryP MYixO|k2PjB6MB?=
ALL3 MmL6R5l1d3SxeHnjJGF{e2G7 NIX6ZoIxNjIQvF2= M{jOUlczKGh? M2LSOWROW09? NYHIZ|huUUN3ME2wMlAxODRizszN M3[2VFE6QDh7NUSw
CML M{L1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\sUmYzOCCvaX6= M2P6PGROW09? NH\TbVNKSzVyPUCuNFAyKM7:TR?= M3O4clE6OjF7MEG2
BA/F3 NXHYV4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUW3NkBp MYjEUXNQ M2PMOGlEPTB;Nj61PFkh|ryP M13IXVI{ODh6NkS0
BA/F3 MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWi3NkBp MoDlSG1UVw>? M3nldmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh|zszN NEO5ZpMzOzB6OE[0OC=>
BA/F3 NUPDWGJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3tO|IhcA>? MlvpSG1UVw>? NYT6[ZlLUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= MXOyN|A5QDZ2NB?=
BA/F3 NV3PfG92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C5UFczKGh? NWDkbZY6TE2VTx?= Moj3TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP NFrqe24zOzB6OE[0OC=>
BA/F3 NV3NVHQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP5dFc4OiCq NFHJTpFFVVOR M4jROWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP MVmyN|MxOTdyMx?=
BA/F3 NIfr[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTGN2U4OiCq NIO2UIdFVVOR MkPOTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1? NVfMeVlOOjN|MEG3NFM>
BA/F3 M1HhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3NkBp MlrVSG1UVw>? NEnQRXVKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= MkH3NlM{ODF5MEO=
BA/F3 M2TzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTkb2xNPzJiaB?= MnzPSG1UVw>? MnTQTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>? MmLGNlM{ODF5MEO=
BA/F3 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rlTFczKGh? M4f4dmROW09? MmXpTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1? NIXGcZgzOzNyMUewNy=>
BA/F3 NIXiclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIftN|c4OiCq MoGzSG1UVw>? MVnJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> NVLmTlVFOjN|MEG3NFM>
BA/F3 M3PUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fMUVczKGh? M3ruemROW09? NYTp[HhJUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2= MlHvNlM{ODF5MEO=
BA/F3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHkO|IhcA>? MVHEUXNQ Mn;YTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0> NG\Gb|czOzNyMUewNy=>
BA/F3 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDsO|IhcA>? MX\EUXNQ Ml;xTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NIjlSIYzOzNyMUewNy=>
T cell NVXEb3FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom5O|IhcA>? M2rUUWROW09? M1rhR2lvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO M{ftUlE4OTV2NUGy
WiDr M3HPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq2O|IhcA>? M{j6d2ROW09? M1HEfGlEPTB;MD6wOVIh|ryP MYKxOVYyPTVzMh?=
PC3 M4XyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLxO|IhcA>? M2nQOmROW09? M3zyXWlEPTB;MD6wNFk1KM7:TR?= NHy1OJUyPTZzNUWxNi=>
MDA-MB-231 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nCU|czKGh? NVfHWFB1TE2VTx?= Ml\LTWM2OD1yLkCxNkDPxE1? Mo\UNVU3OTV3MUK=
Hs578T MVPDfZRwfG:6aXOgRZN{[Xl? NFXxSJg4OiCq M3r1dmROW09? NVW0ZYVsT0l3ME2wMlA{KM7:TR?= MVyyOFAyPTN{Nx?=
HMEC Mlv6R5l1d3SxeHnjJGF{e2G7 NXewSZVKPzJiaB?= NWrOVnlITE2VTx?= NX\NToc4T0l3ME2xMlgh|ryP MkfENlQxOTV|Mke=
DU145 M2HkSGN6fG:2b4jpZ{BCe3OjeR?= MYC3NkBp NV7FOJo{TE2VTx?= M{HCWWdKPTB;MD6xOkDPxE1? NXjMZVdIOjRyMUWzNlc>
U251 MXPDfZRwfG:6aXOgRZN{[Xl? NVTMV2p5PzJiaB?= NELhOFZFVVOR M2PuRWdKPTB;Mj64NUDPxE1? MkLUNlQxOTV|Mke=
NCI60 M4\QXmN6fG:2b4jpZ{BCe3OjeR?= M3X3PFczKGh? MYPEUXNQ MV7HTVUxRTVwNzFOwG0> MX2yOFAyPTN{Nx?=
MALME-3M M3:1[2N6fG:2b4jpZ{BCe3OjeR?= M{L5XFczKGh? NWGyWnllTE2VTx?= MUnHTVUxRTZwNkGg{txO MnPjNlQxOTV|Mke=
KM12 M2jHNGN6fG:2b4jpZ{BCe3OjeR?= NF\ibZE4OiCq NYDqUnJYTE2VTx?= M37HU2dKPTB;Nz60OEDPxE1? NUPIZ2ZCOjRyMUWzNlc>
SW620 MUfDfZRwfG:6aXOgRZN{[Xl? MVW3NkBp MV7EUXNQ MkD0S2k2OD16LkSzJO69VQ>? MWqyOFAyPTN{Nx?=
RXF 393NL M1LadGN6fG:2b4jpZ{BCe3OjeR?= MVW0JIRigXN? MlPWSG1UVw>? M3;VWGlEPTB;MD6wNlE4KM7:TR?= NIrke5MzOzJ3M{C3OC=>
LXFA 983L NUPwT|k6S3m2b4TvfIlkKEG|c3H5 NYfVd5R[PCCmYYnz NGrzcFlFVVOR MV;JR|UxRTBwMEW2OUDPxE1? MWKyN|I2OzB5NB?=
PRXF DU145 NWW4cVVxS3m2b4TvfIlkKEG|c3H5 NFvHOVU1KGSjeYO= Mnr1SG1UVw>? MXfJR|UxRTBwME[yN{DPxE1? NVP1TmFWOjN{NUOwO|Q>
PAXF 1657L NEjIbXFEgXSxdH;4bYMhSXO|YYm= NYPWfmRDPCCmYYnz M2f5TGROW09? NIG0flFKSzVyPUCuNVIyKM7:TR?= NXLWZ|kzOjN{NUOwO|Q>
CXF 1103L MWrDfZRwfG:6aXOgRZN{[Xl? NVz3T4Q3PCCmYYnz M1HCPGROW09? MW\JR|UxRTRwM{[g{txO M2fV[|I{OjV|MEe0
GXF251L MkPaR5l1d3SxeHnjJGF{e2G7 MmK3OEBl[Xm| M2juWmROW09? NIHmfI5KSzVyPUKuNlUh|ryP M2jnUVI{OjV|MEe0
NCI-H23 NUnrbWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfaPFE4OiCq M12wN2ROW09? MWPJR|UxRTJwMkeg{txO MmP2NlM2OjFyMkC=
HCT116 MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjjU2lMPzJiaB?= M{TLVGROW09? MnzHTWM2OD1{LkOg{txO NYKwfoRiOjN3MkGwNlA>
MCF7 NEfwNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnFSFI4OiCq MU\EUXNQ Mnz4TWM2OD1{LkW3JO69VQ>? NUTzXXVpOjN3MkGwNlA>
NCI-H460 NGLZbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\MO|IhcA>? MXnEUXNQ NYDtPGp1UUN3ME24Mlk6KM7:TR?= MYiyN|UzOTB{MB?=
DLD1 NYe4TplHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2wSpVXPzJiaB?= NX;CUVQxTE2VTx?= M3rhS2lEPTB;ND62JO69VQ>? NIXBVoIzOzV4N{m2NC=>
NCI-H661 NYnGboM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;4UWJ6PzJiaB?= MWjEUXNQ MkD2TWM2OD15Lkig{txO NGroO2wzOzV4N{m2NC=>
A549 MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\5O|IhcA>? MmSySG1UVw>? MWPJR|UxRThwMjFOwG0> NIe2c3YzOzV4N{m2NC=>
U937 NYLsWHZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\OTFczKGh? M{PXcGROW09? MnjTTWM2OD1zMj6yJO69VQ>? MWCyN|U3Pzl4MB?=
HEK293 NFLCVYtHfW6ldHnvckBCe3OjeR?= NH:3NJEyOMLizszN MlPLSG1UVw>? MX3JcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= M3TGc|IzPzdyNkGw
HUVEC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSwMlE2yqEQvF2= MljLO|IhcA>? NH;3R3ZFVVOR Ml\zTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDheEAxNjF3IIXN MmPkNlI5PTN7OUO=
HUVEC NXrtdVZITnWwY4Tpc44hSXO|YYm= MnHKNVXDqM7:TR?= M1nGTFczKGh? MkmxSG1UVw>? M{TpVGlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO M4DnWFIzQDV|OUmz
Plasmodium falciparum M3fwU2Z2dmO2aX;uJGF{e2G7 MUCxNOKh|ryP MXyxOUBucW5? NVHMWXdnTE2VTx?= MoLETY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO MWGyOFU2ODN|MB?=
PC3 NXHZTGZQTnWwY4Tpc44hSXO|YYm= MlHHNE4yKM7:TR?= M1GzU|UhcA>? M1zRVmROW09? M3;0N2lvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= MYCxPVQ3Ojl5NR?=
DU145 NILTTWVHfW6ldHnvckBCe3OjeR?= M2\xe|AvOSEQvF2= NIS4[5E2KGh? NIDJVnFFVVOR MlHoTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= MX:xPVQ3Ojl5NR?=
PC3 NHuyNpBMcW6jc3WgRZN{[Xl? NVrMUIJWOC5zIN88US=> M1XUfVUhcA>? NWPw[WZyTE2VTx?= MonsTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= MljNNVk1PjJ7N{W=
DU145 M{L6VGtqdmG|ZTDBd5NigQ>? M{HCe|AvOSEQvF2= NHvvdmo2KGh? NIT4XmRFVVOR NGD0S2NKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> MlHmNVk1PjJ7N{W=
PC3 MkXUT4lv[XOnIFHzd4F6 MlqzNE4yKM7:TR?= M{DaWVUhcA>? M2X0dWROW09? MnLkTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O MWKxPVQ3Ojl5NR?=
DU145 MoS1T4lv[XOnIFHzd4F6 MXSwMlEh|ryP Mon4OUBp MYnEUXNQ MoCwTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? NH;SUWYyQTR4Mkm3OS=>
Huh7 MVrBcpRqfmm{YXygRZN{[Xl? MYeyMlUh|ryP MmjCOEBl[Xm| MnTFSG1UVw>? NV\qdGtCUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN M1vFWlE4OzZyNke2
C6/36 M{XBUmFvfGm4aYLhcEBCe3OjeR?= MUGyMlUh|ryP MWG0JIRigXN? NYLuRo0{TE2VTx?= MULJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO NGnMT5cyPzN4ME[3Oi=>
U937 NFfIO2VHfW6ldHnvckBCe3OjeR?= MlLHNUDPxE1? NV3lR2dUOSCq MlOwSG1UVw>? NWjFcW5uWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= MlX5NVc3QDRyOUm=
U937 M2SyZWZ2dmO2aX;uJGF{e2G7 Mn62NUDPxE1? Mmj2NUBp M4TsR2ROW09? NFHVSJVT\WS3Y3XzJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? NHz0d3EyPzZ6NEC5PS=>
murine mast cell NX3meFNuTnWwY4Tpc44hSXO|YYm= MnG0NUDPxE1? M3XqbVI1KGh? NYnDZ4lxTE2VTx?= NGnC[ZhKdmirYnn0d{BidnSrZ3XuMYlv\HWlZXSgTWw3KHOnY4LleIlwdiCrbjDJ[2UheHKrbXXkJI1wfXOnIH3hd5Qh[2WubIOgZZQhOSC3TR?= M4DOSFE4Pjh2MEm5
BV-173 NYnjZ25MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmwTWM2OD1yLkCwNFAxODFyOTFOwG0> NX3F[246W0GQR1XS
K-562 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnofWY2UUN3ME2wMlAxODByMEK2OkDPxE1? MlG1V2FPT0WU
BL-70 NX\oPXQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\nc|BCUUN3ME2wMlAxODByMEiyNkDPxE1? NWrQT2xUW0GQR1XS
EM-2 NXXhTXNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KyW2lEPTB;MD6wNFAxODFyODFOwG0> NVnneo1SW0GQR1XS
LAMA-84 M3S0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMECwNFA{OjFizszN Mlm1V2FPT0WU
MEG-01 M4XoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV63coxzUUN3ME2wMlAxODByOUig{txO MmPtV2FPT0WU
EoL-1-cell MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMECwNFE{OSEQvF2= MkP0V2FPT0WU
CTV-1 NITjPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj1TWM2OD1yLkCwNFA1ODRizszN NF3KZ5dUSU6JRWK=
TE-15 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq4[VFKSzVyPUCuNFA2QDlizszN NYrHSodnW0GQR1XS
NOS-1 M4exbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMEC2NVMh|ryP MoXTV2FPT0WU
D-336MG M{K1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPwU4lKSzVyPUCuNFA3OyEQvF2= NFThcVJUSU6JRWK=
LB1047-RCC M{Hmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEC5PFkh|ryP NYTLfZBLW0GQR1XS
LB996-RCC MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX6eVlOUUN3ME2wMlAxQTlzIN88US=> MW\TRW5ITVJ?
SW982 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ixNWlEPTB;MD6wNVEyPSEQvF2= NFXXelRUSU6JRWK=
TK10 NVLPXmpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEGxO|Qh|ryP MlrFV2FPT0WU
A704 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnPUIg{UUN3ME2wMlAyPDlzIN88US=> NXO0c5NZW0GQR1XS
TE-8 NXnuR49NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XVV2lEPTB;MD6wNVU4PiEQvF2= NWXmfJJvW0GQR1XS
DOHH-2 M4fwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrBemxKSzVyPUCuNFE4OTlizszN NF7sOHFUSU6JRWK=
HOP-62 NWfiPZlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMEG4N|Qh|ryP MmiwV2FPT0WU
TE-12 M1v0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMEG4OlEh|ryP M3XlZXNCVkeHUh?=
KGN Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEG5OFIh|ryP MX7TRW5ITVJ?
NCI-H1648 NXjGbXJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzCTWM2OD1yLkCyNFEyKM7:TR?= MlP6V2FPT0WU
OS-RC-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\xRWlEPTB;MD6wNlA{KM7:TR?= NYHQ[JFQW0GQR1XS
GB-1 NFPRfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mW5pKSzVyPUCuNFIyPTdizszN MmfOV2FPT0WU
RXF393 M4f6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEKzOVch|ryP MVHTRW5ITVJ?
LC-2-ad MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPQTWM2OD1yLkCyOVg3KM7:TR?= NX;Vb3oxW0GQR1XS
KS-1 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn61TWM2OD1yLkCyO|Mh|ryP NYPS[XlPW0GQR1XS
ETK-1 NVzMO48yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMEK4N|Ih|ryP M37LeHNCVkeHUh?=
SW954 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzjNJhKSzVyPUCuNFI6OjdizszN NIHrTWZUSU6JRWK=
Becker NFPFVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jqOWlEPTB;MD6wN|AxOyEQvF2= NV;MfFNkW0GQR1XS
MZ1-PC M3;YOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP5dFBKSzVyPUCuNFMyOTlizszN M4nlXnNCVkeHUh?=
ES6 M1\qOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEOxPVMh|ryP NVrHOJgyW0GQR1XS
KURAMOCHI MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzGZWFOUUN3ME2wMlA{PDh5IN88US=> NXHEWXhzW0GQR1XS
CGTH-W-1 M3T6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEO1OFgh|ryP M2LTZnNCVkeHUh?=
VA-ES-BJ NViyd4VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LJXmlEPTB;MD6wN|kxOiEQvF2= M{i3XXNCVkeHUh?=
LXF-289 NWr4TZo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7oTWM2OD1yLkCzPVU3KM7:TR?= NGPBc2tUSU6JRWK=
MPP-89 NF;YO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMESwOFkh|ryP NF3v[4hUSU6JRWK=
SW872 M3LiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP3TWM2OD1yLkC0NVYyKM7:TR?= Mn\EV2FPT0WU
SNB75 NX\CeVNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3THUGlEPTB;MD6wOFQ{PSEQvF2= NYHJWY02W0GQR1XS
PSN1 NGrifZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfh[G1KSzVyPUCuNFQ1PzRizszN M4DEXXNCVkeHUh?=
LB831-BLC M{iw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPSTWM2OD1yLkC0OlA6KM7:TR?= MVzTRW5ITVJ?
MFH-ino MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLFfVc3UUN3ME2wMlA1PzJ2IN88US=> NGrB[JRUSU6JRWK=
TGBC24TKB MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjKOYc5UUN3ME2wMlA1PzZzIN88US=> MXHTRW5ITVJ?
A388 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zjV2lEPTB;MD6wOVA6PSEQvF2= Mlu2V2FPT0WU
BB30-HNC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEW0N|ch|ryP MmX4V2FPT0WU
GI-ME-N M3HCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jTOGlEPTB;MD6wOlEyQCEQvF2= NWT1d2hyW0GQR1XS
TGBC1TKB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwME[xOlQh|ryP Mmq3V2FPT0WU
TE-10 M4H5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G5VGlEPTB;MD6wOlM2PyEQvF2= MV7TRW5ITVJ?
A498 NUjyU29MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMEeyPFQh|ryP M3;VV3NCVkeHUh?=
TE-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;WNGlEPTB;MD6wO|g2QCEQvF2= NVzIdWllW0GQR1XS
BB65-RCC Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fOemlEPTB;MD6wPFIzPyEQvF2= MVnTRW5ITVJ?
C2BBe1 NIXP[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXZVYxKSzVyPUCuNFg{ODhizszN NWm0OZRTW0GQR1XS
NCI-H747 NGDtWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLqXmdUUUN3ME2wMlA5OzZ{IN88US=> M13BUnNCVkeHUh?=
IST-MES1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml20TWM2OD1yLkC4OVUzKM7:TR?= M1WwbXNCVkeHUh?=
KALS-1 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3QS2hKSzVyPUCuNFk1QSEQvF2= NGTreWRUSU6JRWK=
GCIY M{Oze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\qNFNxUUN3ME2wMlA6PjV4IN88US=> M3LySnNCVkeHUh?=
RL95-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfUXZpoUUN3ME2wMlExOzhizszN MXjTRW5ITVJ?
TE-1 M{[0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13JNGlEPTB;MD6xNFU1KM7:TR?= Mo[yV2FPT0WU
NCI-H1355 M3W4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMUGwNlgh|ryP NYr2cJZlW0GQR1XS
SW962 NG\OTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrXXI1KSzVyPUCuNVEzQTJizszN M1HkNXNCVkeHUh?=
KLE NHvrTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n1fmlEPTB;MD6xNVMyPyEQvF2= MYTTRW5ITVJ?
MC116 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC0TWM2OD1yLkGxOFEh|ryP MnvNV2FPT0WU
NMC-G1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMUG2NFYh|ryP M3nJNnNCVkeHUh?=
KU812 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnyTWM2OD1yLkGxPFg{KM7:TR?= Ml:4V2FPT0WU
COLO-829 NVew[HRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMUKyNVMh|ryP MmGxV2FPT0WU
NTERA-S-cl-D1 M{H3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\mTWM2OD1yLkGyNlg{KM7:TR?= NYC0Nm1rW0GQR1XS
IST-MEL1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PGSGlEPTB;MD6xN|Q2KM7:TR?= NY[xcFY2W0GQR1XS
MLMA MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zTZWlEPTB;MD6xOFA{OiEQvF2= MYLTRW5ITVJ?
LS-123 NUTpNml7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33Xc2lEPTB;MD6xOFA3PCEQvF2= NFKxSXpUSU6JRWK=
LB2518-MEL NHfsNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HVVGlEPTB;MD6xOFE3OiEQvF2= MXfTRW5ITVJ?
NB69 NYHTfVA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrHcYllUUN3ME2wMlE1PDN4IN88US=> NU\ZTlA2W0GQR1XS
8-MG-BA NWrsWo1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHIT4FwUUN3ME2wMlE2PDV6IN88US=> NFzPbZdUSU6JRWK=
K5 M3;0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\Td4d4UUN3ME2wMlE3PDh7IN88US=> NHHXVWRUSU6JRWK=
KINGS-1 M2\J[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMU[2OlYh|ryP NUXBV3F2W0GQR1XS
SF268 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDGTWM2OD1yLkG3OFA1KM7:TR?= NXr1dlUzW0GQR1XS
PF-382 NX7SbFlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyxTnZKSzVyPUCuNVc3PzhizszN MoTLV2FPT0WU
SH-4 NV:xTHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMUi0NVMh|ryP NWC5b3Y4W0GQR1XS
NALM-6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37WcmlEPTB;MD6xPVI6PSEQvF2= M{fxPHNCVkeHUh?=
CP66-MEL MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTQR5Y{UUN3ME2wMlE6PTNzIN88US=> NUS5eJdPW0GQR1XS
697 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfUTWZKSzVyPUCuNVk6QDdizszN M17JU3NCVkeHUh?=
CP67-MEL MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C5NWlEPTB;MD6yNFQ5QCEQvF2= MXvTRW5ITVJ?
DSH1 M1HXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHBOWpOUUN3ME2wMlI1ODBzIN88US=> Ml\YV2FPT0WU
HCE-4 M4D5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\PPWlEPTB;MD6yOlQ{QSEQvF2= M3;B[XNCVkeHUh?=
MZ2-MEL Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z6W2lEPTB;MD6yPFU{PyEQvF2= M1fQcXNCVkeHUh?=
BL-41 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\zTWM2OD1yLkK5NVI{KM7:TR?= MlHBV2FPT0WU
HUTU-80 NHjTSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwM{G0NkDPxE1? Ml35V2FPT0WU
LOXIMVI MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPEc|Q3UUN3ME2wMlMyPTB|IN88US=> MYrTRW5ITVJ?
no-10 NH7lSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW2TWM2OD1yLkOxPVMyKM7:TR?= NFjhO3hUSU6JRWK=
KARPAS-422 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\WTWM2OD1yLkOzPVk4KM7:TR?= NE\yPWVUSU6JRWK=
SW684 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17GZmlEPTB;MD6zOFk5KM7:TR?= NH7aNW5USU6JRWK=
SF126 NEXzdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwM{W0NUDPxE1? MmHnV2FPT0WU
D-263MG MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorrTWM2OD1yLkO2NlI1KM7:TR?= MVfTRW5ITVJ?
OVCAR-4 NFTnUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO3UHZKSzVyPUCuN|c1OzNizszN MX7TRW5ITVJ?
BB49-HNC M3Gxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;6fmlEPTB;MD6zPFU6QSEQvF2= M4fseHNCVkeHUh?=
ONS-76 M1\xfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm0Z4pqUUN3ME2wMlQzQTVzIN88US=> NVH0eWU2W0GQR1XS
MZ7-mel Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG3TWM2OD1yLkS3PVEyKM7:TR?= NYjBSm9VW0GQR1XS
RCC10RGB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNEmxNUDPxE1? Mnn6V2FPT0WU
BOKU NHTpVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwNEmxN|Mh|ryP Ml7tV2FPT0WU
no-11 M3[4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwNUCyNlgh|ryP MUfTRW5ITVJ?
IST-SL2 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr3UlhKSzVyPUCuOVA{ODJizszN NInkfZhUSU6JRWK=
RKO NEDZ[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PVfWlEPTB;MD61Nlk3PiEQvF2= NGTFZpBUSU6JRWK=
HT-144 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTsTWM2OD1yLkWzOlA6KM7:TR?= MoLZV2FPT0WU
NCI-H446 M3nJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe1S2hKSzVyPUCuOlI4PiEQvF2= NVntWlVZW0GQR1XS
QIMR-WIL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX4VmRKSzVyPUCuO|A3OjlizszN M4DkUHNCVkeHUh?=
MHH-PREB-1 NHHqVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\jc4pKSzVyPUCuO|Q1PjlizszN NXr2dpdEW0GQR1XS
EW-16 NV\oWmxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TJeWlEPTB;MD63OlE4QCEQvF2= MYrTRW5ITVJ?
EW-24 NUXWdGlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwN{ixOlUh|ryP NYfpSFJnW0GQR1XS
LB373-MEL-D NF3v[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jwU2lEPTB;MD64NlUxQCEQvF2= MmS5V2FPT0WU
TE-9 M{DmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELz[2lKSzVyPUCuPFc2OzJizszN NGPVV3BUSU6JRWK=
A3-KAW NGrwVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzCWI5KSzVyPUCuPVg1PTJizszN M1HpTHNCVkeHUh?=
A101D NYTTVI43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3qXIZKSzVyPUGuNFMxPDNizszN MlPaV2FPT0WU
OCUB-M NUjhe5MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PsSWlEPTB;MT6wOFQyOiEQvF2= MXrTRW5ITVJ?
ES4 M2m5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHITWM2OD1zLkC1NVQ2KM7:TR?= M3TUNXNCVkeHUh?=
TE-6 M{LY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfDUFRrUUN3ME2xMlIyOjJ4IN88US=> NFr0eGZUSU6JRWK=
D-502MG NYGx[|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMkOzO|Yh|ryP MnXsV2FPT0WU
KNS-42 NXj4bpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\ZXIVLUUN3ME2xMlI1PDF{IN88US=> Ml7BV2FPT0WU
SNU-C2B NVLRZndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXtb2pKSzVyPUGuN|A2QDlizszN NEPqc5NUSU6JRWK=
NCI-H1838 Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XPV2lEPTB;MT6zNFc{OyEQvF2= M2nRXXNCVkeHUh?=
NKM-1 NF7wNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\nVHJKSzVyPUGuN|A5PTlizszN M3HrW3NCVkeHUh?=
GI-1 MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfLZW1KSzVyPUGuN|YzOiEQvF2= NIXHbIJUSU6JRWK=
NB5 NULDUo0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy4d4dKSzVyPUGuN|k5OjdizszN NFjT[YxUSU6JRWK=
CAS-1 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwNEC5PVIh|ryP NFW2VFVUSU6JRWK=
HCE-T M{i2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHaTIk{UUN3ME2xMlU3PzF2IN88US=> MnOyV2FPT0WU
SBC-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFwNUe5PFQh|ryP NGDwd5pUSU6JRWK=
JiyoyeP-2003 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITWWGZKSzVyPUGuO|M1PjZizszN M1zvNHNCVkeHUh?=
TE-5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHIfHJKUUN3ME2xMlc6OTN7IN88US=> NULYcVZxW0GQR1XS
CAN M1HISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDrZoRKSzVyPUGuPFIzPTJizszN NFX1XZBUSU6JRWK=
SK-UT-1 M4W1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK2UVFKSzVyPUKuNVY3QTNizszN Ml;IV2FPT0WU
JVM-2 NU[xXY81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzQNGJKSzVyPUKuN|YzQDRizszN Mnj1V2FPT0WU
LB771-HNC M3y4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;LTWM2OD1{LkW3OVUyKM7:TR?= NGjFdpNUSU6JRWK=
NCCIT NI\h[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3BTWM2OD1{Lki2OlE3KM7:TR?= NIrzU3FUSU6JRWK=
NCI-H2126 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofKTWM2OD1{Lki3OVUzKM7:TR?= NInMelVUSU6JRWK=
Calu-6 NHSwblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\hfZl6UUN3ME2zMlA2PzRzIN88US=> NFL3fY9USU6JRWK=
SK-LMS-1 NYi4cXU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPkZoE2UUN3ME2zMlEyQDh4IN88US=> NFvu[5pUSU6JRWK=
ARH-77 NInFWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7COIlKSzVyPUOuOFY6OTVizszN NHHlUGpUSU6JRWK=
NB17 Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNwNkO4OFch|ryP M4fLT3NCVkeHUh?=
A253 M4\ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\1NYRSUUN3ME2zMlc{OjR4IN88US=> Ml;hV2FPT0WU
OPM-2 NUXhbWFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTRwMke2PFUh|ryP NGP3[WVUSU6JRWK=
MV-4-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwM{[0OVQh|ryP Mke0V2FPT0WU
SR M{O1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\1bIlkUUN3ME20MlQ6QTV2IN88US=> NWrpb|liW0GQR1XS
KG-1 M3P6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvpTWM2OD12Lk[wPFQ2KM7:TR?= NHu2bmlUSU6JRWK=
OCI-AML2 M1fkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi5OmR2UUN3ME21Mlg3OTV2IN88US=> NXf4e|dWW0GQR1XS
D-247MG M2mxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\ITmFKSzVyPU[uNVI2OTlizszN Mn;EV2FPT0WU
DJM-1 NIDCbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3GTWM2OD14LkS4OVU5KM7:TR?= NITqNIJUSU6JRWK=
RPMI-6666 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjwfVJiUUN3ME23MlI4ODZ5IN88US=> NUfKXmZpW0GQR1XS
KARPAS-45 NG\3RVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrMVGtKSzVyPUeuOVE3PzFizszN MXXTRW5ITVJ?
LP-1 NEflWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuzbFRMUUN3ME23MlU1Pzh{IN88US=> MYDTRW5ITVJ?
RS4-11 MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTdwNkW3PFch|ryP NU\Se|k1W0GQR1XS
DU-4475 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ZTWM2OD16LkKxOlUzKM7:TR?= NGfnPYZUSU6JRWK=
MONO-MAC-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjzTWM2OD16LkK3NFY3KM7:TR?= MkWwV2FPT0WU
NCI-SNU-16 NXnCbIpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn0XmdFUUN3ME24MlU3OTJ6IN88US=> M2HB[XNCVkeHUh?=
SJSA-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRThwN{K4NFUh|ryP M{[1dHNCVkeHUh?=
MMAC-SF NFXS[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRThwN{mzNFch|ryP NXrpOW5KW0GQR1XS
SK-NEP-1 NHftS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRThwOEmxOVUh|ryP M4[5VnNCVkeHUh?=
J-RT3-T3-5 NHXDSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPkTFRKSzVyPUiuPVY2OjlizszN NE\BOI1USU6JRWK=
SKM-1 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rwXGlEPTB;OT6wNVc{PCEQvF2= MX\TRW5ITVJ?
LB2241-RCC MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTlwMEKwNVIh|ryP MUDTRW5ITVJ?
SIG-M5 NIfUUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTlwMEK0PVMh|ryP M3naTHNCVkeHUh?=
EVSA-T MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTWT3dJUUN3ME25MlI4Pzl|IN88US=> NHLGeotUSU6JRWK=
GT3TKB M{fqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTlwM{W1OFYh|ryP M1rsU3NCVkeHUh?=
NB6 M3jsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS5bYFKSzVyPUmuPVIzPTlizszN MWXTRW5ITVJ?
EHEB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfRfpJKSzVyPUGwMlA3PTZizszN MUjTRW5ITVJ?
HEL NUXQOW1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\nXGlEPTB;MUCuOFc4PiEQvF2= NIP3NXlUSU6JRWK=
ALL-PO MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrMTWM2OD1zMD63PVM5KM7:TR?= M4i5RnNCVkeHUh?=
TGW M1z1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3qSHZKSzVyPUGxMlI5OjhizszN MkmzV2FPT0WU
BC-3 NUL5PYxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULoSIwyUUN3ME2xNk4yOTN6IN88US=> M3fOXnNCVkeHUh?=
IA-LM MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF{LkS0OFUh|ryP NHe0ZXpUSU6JRWK=
UACC-257 NYHaNGNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF{LkmxPVgh|ryP NXHOOWJ2W0GQR1XS
KP-N-YS NUH5WJl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHflT3pKSzVyPUGyMlkzQDNizszN MofPV2FPT0WU
Raji NIjNUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTWXZZsUUN3ME2xN{44PDl5IN88US=> MVfTRW5ITVJ?
SF539 NWmwSmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PWSGlEPTB;MUOuPFU2PyEQvF2= M{fobnNCVkeHUh?=
DMS-153 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF2LkCwNlgh|ryP M1T3SHNCVkeHUh?=
L-540 NXHncpduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXQTWM2OD1zNT6wOlczKM7:TR?= MXfTRW5ITVJ?
MN-60 M1u2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF3LkG5O|kh|ryP NGm2b4VUSU6JRWK=
RPMI-8866 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF5LkS0OVQh|ryP M3HxS3NCVkeHUh?=
NCI-H510A NEHxcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHBTWM2OD1zOT6zPVc{KM7:TR?= MXvTRW5ITVJ?
NB13 Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF7LkS4O|ch|ryP NF7HNnZUSU6JRWK=
HAL-01 NHzQR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;DSnc{UUN3ME2xPU44PTR|IN88US=> NGLaUGFUSU6JRWK=
NCI-H720 MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17yTWlEPTB;MkCuNlc{OyEQvF2= MXTTRW5ITVJ?
REH NX3YXGpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGxTWM2OD1{MD62N|U4KM7:TR?= NFvUOm1USU6JRWK=
KNS-81-FD MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17ORWlEPTB;MkOuNVQ3KM7:TR?= MVjTRW5ITVJ?
HC-1 NWHzXlh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHVTWM2OD1{ND61OVUyKM7:TR?= M2TRS3NCVkeHUh?=
NCI-H2141 NWW4WmJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ2Lke3OVQh|ryP NX2wbmJXW0GQR1XS
MOLT-4 M1eyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ4Lk[3OVMh|ryP NH:zVm9USU6JRWK=
OMC-1 M3vXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{iwUGlEPTB;MkeuNVQzOiEQvF2= NWD1WYw4W0GQR1XS
LC-1F NWPhWIdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJ5LkOyOFUh|ryP MUHTRW5ITVJ?
NCI-H1304 NV24SJJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjhTWM2OD1{OD6xOlI5KM7:TR?= NX\jc3V4W0GQR1XS
BC-1 NVHSTnJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jmbGlEPTB;MkiuOlUyKM7:TR?= M1fzOnNCVkeHUh?=
NCI-H64 M1fjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvqcJZKSzVyPUK5MlYzPTNizszN M4\o[3NCVkeHUh?=
MOLT-16 NVv6VmJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonsTWM2OD1{OT62NlkzKM7:TR?= NH\j[YJUSU6JRWK=
U-87-MG M1nvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXUU2dIUUN3ME2zNE44PjZizszN Mn7BV2FPT0WU
GAK M{f3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PETGlEPTB;M{GuNlY5PiEQvF2= M13mXXNCVkeHUh?=
ES8 NVzhcJBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFewcFlKSzVyPUOyMlEzPTJizszN MVzTRW5ITVJ?
HCC1599 M1;ET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN{LkOzNlUh|ryP MWDTRW5ITVJ?
EB-3 NGToRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG1OWpZUUN3ME2zOE4{OTF5IN88US=> MVrTRW5ITVJ?
HCC1187 NFTkbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjGWnhKSzVyPUO1MlgxPTJizszN MYfTRW5ITVJ?
SK-PN-DW MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rr[2lEPTB;M{[uNVk1OyEQvF2= NHPrTotUSU6JRWK=
JVM-3 MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXKZmxtUUN3ME2zO{4zOzN6IN88US=> MmjSV2FPT0WU
HCC2157 M3;XZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnxTmtKSzVyPUO3Mlk6PDZizszN NEPLT3RUSU6JRWK=
A4-Fuk NGXtSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnBTWM2OD1|OD6xNFA6KM7:TR?= M3zC[HNCVkeHUh?=
COR-L279 M4\WUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSwTWM2OD12MD6yPFUyKM7:TR?= NUXoc5ZVW0GQR1XS
DEL M1rGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTRzLkmwPFYh|ryP M1S3fHNCVkeHUh?=
NCI-H1395 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zpOmlEPTB;NEKuNFE3OyEQvF2= NGLwSlhUSU6JRWK=
MHH-NB-11 NHvMSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS5[JllUUN3ME20N{4xQDF6IN88US=> MlTqV2FPT0WU
NCI-H2107 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHLTWM2OD12Mz60PFQ3KM7:TR?= MVHTRW5ITVJ?
NEC8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m0c2lEPTB;NESuN|M3KM7:TR?= MXLTRW5ITVJ?
COLO-684 NYPPdm5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrkfVdKSzVyPUS2MlIzPThizszN NGjkOodUSU6JRWK=
LS-411N NU\jRpNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWy[YxHUUN3ME20PE41PzR6IN88US=> MWrTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
細胞試験:

[1]

+ 展開
  • 細胞株: Ba/F3 cell lines
  • 濃度: ~32 nM
  • 反応時間: 72 hours
  • 実験の流れ:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • 製剤: DMSO
  • 投薬量: 30 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管
in solvent
別名 BMS-354825

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 質問2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Srcシグナル伝達経路

Src Inhibitors with Unique Features

相関Src製品

Tags: Dasatinibを買う | Dasatinib ic50 | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib化学構造 | Dasatinib分子量 | Dasatinib代理店
×

大阪市内で「G20サミット」が開催されることに伴い、大阪府内で大規模な交通規制が行われる影響で、6月26日(水)から7月1日(月)までの間、下記地域へ出荷が行えなくなります。
対象地域
大阪府(全域)、兵庫県(芦屋市、尼崎市、伊丹市、西宮市)
上記地域より西の地域につきましては納期の遅延が予想されます。
また、国際便も遅延が予想されているため国内在庫がない製品の納期が一週間程度遅れる可能性がございます。
ご不便をおかけいたしますが、宜しくお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID